A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Investigator: Hanh Mai, MD

Study Coordinator: Rabia Hashmani

Status: Enrolling

ClinicalTrials.gov Number: NCT05629585

Phone: 346.238.5894

Protocol Number: PRO00037085

Description

This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.
More to Explore
Search Clinical Trials
Join a Clinical Trial
Clinical Research Support Services for Investigators
Weill Cornell Medical College Clinical Trials